Article · 29 Aug 2026
Research articlePublished 4 Mar 2021
A COVID-19 Transmission Model Informing Medication Development and Supply Chain Needs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: We present a country-specific, modified Susceptible, Exposed, Infectious, and Removed (SEIR) model of SARS-CoV-2 transmission aiming to provide accurate prediction of COVID-19 cases to optimize clinical trial recruitment, inform mitigation strategies, and facilitate rapid medication development. Methods: Epidemiological data from more than 170 countries were obtained from the Johns Hopkins University COVID-19 Dashboard. Intercountry differences in initial exposure, cultural/environmental factors, and stringency of mitigation strategies were incorporated. Asymptomatic patients and “super-spreaders” were also factored into our model. Simulations were limited to a period of 2 months considering that the effects of certain parameters (e.g. seasonality of virus transmission, wearing of face masks, and deployment of vaccines) were sufficiently ambiguous to limit confidence in a longer simulation period. Results: Using these data, our model estimated 71.5% of cases as asymptomatic. Without mitigation, a mean maximum infection rate of 1.08 cases/day (Intercountry range, 0.68–1.65) was estimated in symptomatic cases. From here, symptomatic and asymptomatic people were estimated to infect 3.39 and 7.71 other people, respectively, suggesting that asymptomatic persons could be responsible for 85% of new infections. An estimated 10.6% of cases were super-spreaders with a 2.86-fold higher transmission rate than average. Mitigation strategies with a stringency index value of ≥ 45% were estimated to be required to reduce the reproduction ratio below 1 for symptomatic cases. Simulated cases over the next 2 months differed between countries, with certain countries (eg, Argentina and Japan) likely to experience an accelerated accumulation of cases. Conclusion: Together, results from our model can guide the distribution of diagnostic tests, impact clinical trial development, support medication development and distribution, and inform mitigation strategies to reduce COVID-19 spread. The large contribution of asymptomatic cases in the transmission also suggests that measures such as wearing masks, social distancing, testing, and vaccination deployment are foundational to slowing the spread of COVID-19.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Vaccines & Vaccination.
Article · 29 Aug 2026
Advances in Adjuvant Development for Enhanced Vaccine Performance and Long-Term Immune Protection
Article · 20 Jun 2026
Herd Immunity and Its Role in Controlling Infectious Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Annabelle Lemenuel-Diot”
- BylineArticles whose byline prints “Barry Clinch”
- BylineArticles whose byline prints “Aeron C. Hurt”
- BylineArticles whose byline prints “Paul Boutry”
- BylineArticles whose byline prints “Johann Laurent”
- BylineArticles whose byline prints “Mathias Leddin”
- BylineArticles whose byline prints “Stefan Frings”
- BylineArticles whose byline prints “Jean Eric Charoin”